Build your blueprint for a healthy future
About Bioscience
Innovative Treatments and Personalized Therapies for a Better Life
Since 2007, Bioscience Institute has established itself as a global leader in cellular, molecular and clinical biology, delivering advanced biomedical solutions for the molecular management of aging-related processes, reproductive and prenatal genomics, longevity programs and primary cancer prevention, stem cell and exosome banking and regenerative and aesthetic medicine applications, supported by GMP-certified cell processing.
Operating across three continents — Europe, Asia, and North America — Bioscience Institute integrates state-of-the-art genomics laboratories, ultra-deep cfDNA sequencing platforms, and GMP-certified cell manufacturing infrastructures within its international network, with operational presence in San Marino, Italy (Rome), the United Arab Emirates (Dubai), and the United States (Boston). The Institute specializes in genomics, mesenchymal stem cell and exosome culture for advanced personalized therapies addressing degenerative and pathological conditions.
Bioscience in USA
Harvard Medical School – Life Lab (Boston, USA)
Bioscience Institute is a global leader in clinical, molecular, and cell biology, dedicated to the early detection, prevention, and molecular management of aging and cancer.
For nearly two decades, Bioscience Institute has been pioneering advanced biomedical technologies that enable clinicians to identify and act on the earliest biological signals of disease and functional decline, long before clinical symptoms appear.
By integrating multi-omics diagnostics, regenerative biotechnology, and AI-enhanced translational research, Bioscience Institute is shaping a new era of molecular longevity, transforming preventive medicine from a reactive approach into a precision-driven biological interception strategy.
Redefining Longevity Medicine & Cancer Prevention
Traditional longevity and cancer prevention programs focus on late-stage biomarkers and symptom-oriented interventions. Bioscience Institute redefines this paradigm by addressing disease at its molecular origin.
Our approach enables:
• Early identification of molecular mechanism driver of aging and cancer
• Longitudinal monitoring of biological aging and genomic stability
• Precision-based prevention and regenerative strategies
• Molecular interception of disease before irreversible pathology develops
This shift allows clinicians and patients to actively manage aging and cancer risk at the biological level, rather than reacting to established disease.
A Global Network of Scientific Excellence
Bioscience Institute operates within an international ecosystem of academic, clinical, and GMP-certified facilities, ensuring seamless integration between research, diagnostics, and therapeutic innovation.
At the core of our leadership is the unique convergence of three foundational scientific domains, unified into a single, scalable platform.
Our Integrated Scientific Platforms
• Clinical Biology
Advanced medical laboratory science and translational diagnostics designed for longitudinal patient monitoring and precision medicine applications.
• Molecular Biology
Ultra-deep circulating cell-free DNA (cfDNA) sequencing, genomics, epigenomics, and multi-omics analytics to identify genomic instability and the molecular drivers of aging and cancer.
• Cell Biology
GMP-certified stem-cell platforms, including secretome and exosome technologies, supporting regenerative, anti-senescence, and tissue-repair strategies.
The integration of these domains enables unprecedented accuracy in health optimization and molecular disease interception.
Proprietary High-Sensitivity Protocols
Bioscience Institute has developed proprietary, high-sensitivity molecular protocols designed to:
• Reveal the root molecular drivers of aging and cancer
• Intercept physio-pathological changes before they become pathological
• Support targeted, precision-based preventive and regenerative interventions
These technologies form the scientific foundation of Bioscience Institute’s leadership in molecular longevity, cancer prevention, and next-generation precision medicine.
Bioscience in San Marino
At Bioscience Institute, we have developed revolutionary protocols for sequencing circulating DNA, designed to identify the key drivers of aging and related diseases.
This breakthrough allows us to deliver precision preventive medicine tailored to each individual’s needs.
Our proprietary technology supported by an advanced IT Platform can detect even the smallest genetic variations that contribute to cellular senescence and tissue degradation, enabling early intervention before clinical symptoms appear.
By integrating our two core areas of expertise — stem cells and cfDNA sequencing — we have positioned ourselves as a leading company in the field of longevity.
Bioscience in Middle East
Dubai HealthCare City – Dubai (UAE)
In 2014, Bioscience Institute founded the first Regenerative Medicine Center in the Middle East, in Dubai, UAE – a world-class excellence. Bioscience offers the most advanced personalized treatments in the world, based on autologous stem cells.
Bioscience offers a Biobank, a Cell Factory and the Clinic for Regenerative Medicine treatments. The Cell Factory processes the expansion and conservation of stem cells from adipose tissue and fibroblasts.
The Aesthetic and Anti-Aging services of Bioscience are unique in the world as they offer the most advanced autologous cell therapies. The Group of Bioscience facilities works only at the highest level of excellence and includes cell banks, clean rooms and clinics.
Bioscience in Italy
Department of Biology Università degli Studi di Roma “Tor Vergata” (Rome - Italy)
Bioscience Genomics is a university spin-off founded by Bioscience Institute together with the University of Rome “Tor Vergata”.
The facility is aimed at analyzing the genetic anomalies of the fetus from the tenth week of life through the evaluation of its DNA fragments circulating in the blood of the pregnant mother.
Later on, Bioscience Genomics developed and patented a protocol for the analysis of the risk of solid tumors, based on the sequencing of the circulating free DNA, in healthy individuals.
